# Adimab: Research, Lebanon, United States

> Adimab: Adimab is a leader in the discovery and engineering of fully human monoclonal and multispecific antibodies. Based in Lebanon, United States.

Source: https://millionrounds.com/startup/adimab (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# Adimab

Adimab is a leader in the discovery and engineering of fully human monoclonal and multispecific antibodies.

Funding reported Last round: Venture (Round not Specified)

Research Lebanon, United States

Company summary

- **Founded:** 2007 19 years old
- **Team:** 140 51 to 200 people
- **Funding reported:** $92M in dollars
- **Last round:** Venture (Round not Specified) Jul 2020

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Adimab has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Adimab

Adimab is a leader in the discovery and engineering of fully human monoclonal and multispecific antibodies.

Founded in 2007 and headquartered in Lebanon, New Hampshire, with a secondary location in Mountain View, California, the company focuses on external partnerships for therapeutic antibody development. Adimab has partnered with over 140 pharmaceutical and biotechnology companies, generating more than 650 therapeutic programs and 89 clinical programs. The company utilizes a proprietary yeast-based antibody discovery platform that combines synthetic and immune libraries to produce highly specific and stable antibodies. Adimab offers a range of services, including naïve discovery, antibody engineering, and optimization, as well as AI and machine learning-guided library design. Its client base includes global pharmaceutical companies, biotechnology firms, and academic institutions, all benefiting from Adimab's expertise in advancing therapeutic candidates efficiently.

## What company datasets say Adimab raised

Funding, as reported

Reported in all **$92M** in dollars

Last round **Venture (Round not Specified)**

Last round size **$50M**

Last round date **Jul 2020**

SEC Form D **$12M sold, 2 filings, last Nov 2010**

## Founders and team

From Adimab's own website and the SEC filings it signed: 8 on the team.

- **Philip Chase** Chief Executive Officer
- **Katy Seneca** Vice President, Finance & Accounting
- **Guy Van Meter** Chief Business Officer
- **Ryan McGovern** Chief Financial Officer
- **Kirt Johnson** Senior Director, Product Engineering & Operations
- **Errik B. Anderson** Executive Officer, Director i
- **Robert L. Birnbaum** Executive Officer i
- **Tillman U. Gerngross** Executive Officer, Director i

On the board, as filed i *Fran J. Heller* *Michael J. Ross* *Terrance L. McGuire* *William J. Maris*

## On a portfolio page

Investors who name them

- [LaunchCapital](https://millionrounds.com/fund/launchcapital)

Each firm lists Adimab on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

bi multispecifics chain exchange technology biotechnology research biotechnology yeastbased antibody discovery services custom antibody discovery diverse therapeutic formats fc fab heterodimerization protein engineering platform tailored antibody optimization soluble tcr optimization ai ml guided library design life sciences t cell engagers b2b

Built with from their website

Underscore.js Plupload Jamf Yoast Yoast SEO DocuSign CookieYes Backbone.js Microsoft Email Providers Activa

+8 more

Google Tag Manager Microsoft Intune HPLC Dropbox Hubspot Google Font API Open Graph Graphy

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 8731
- **Region:** New Hampshire
- **Revenue:** $15M a year, as listed

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put Adimab in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)